PF-Atlas › Treatments › Navitoclax
Navitoclax
BCL-2/BCL-XL inhibitor — more potent senolytic than D+Q
Clinical research — In human clinical trials (Phase I–III). How PF-Atlas grades evidence.
Development stage
Phase II
Evidence level
Level 2 (Phase II)
Mechanism class
BCL-2/BCL-XL inhibitor — more potent senolytic than D+Q
Timeline
2-3 years
Risk profile
Medium (thrombocytopenia)
Developer
Multiple centers
Key researchers
T. Bhatt
Overview
More potent senolytic. Dose-limited by platelet apoptosis. Navitoclax + nintedanib combination under evaluation.
How Navitoclax fits into IPF treatment
Navitoclax is classified as Level 2 (Phase II) at the Phase II stage. Explore how it compares to other options and where it sits in the development pipeline:
Other IPF treatments
Medical disclaimer. This page summarizes published research and PF-Atlas model output about Navitoclax for information only. It is not medical advice or a treatment recommendation. Drug availability, approval status and evidence change — verify with a pulmonologist and official sources (FDA, ClinicalTrials.gov) before any decision.